Mesoblast Limited (ASX:MSB)

Australia · Delayed Price · Currency is AUD

2.410

+0.050 (2.12%)

Aug 27, 2026, 4:10 PM AEST

-2.03% (1Y)

Market Cap	3.13B -0.6%
Revenue (ttm)	173.82M +599.2%
Net Income	-83.12M
EPS	-0.06
Shares Out	1.30B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,283,144
Open	2.380
Previous Close	2.360
Day's Range	2.340 - 2.470
52-Week Range	1.880 - 3.310
Beta	0.81
Analysts	Strong Buy
Price Target	3.91 (+63.07%)
Earnings Date	Aug 26, 2026

About Mesoblast

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company’s proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulc... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2004

Employees 81

Stock Exchange Australian Securities Exchange

Ticker Symbol MSB

Full Company Profile

Financial Performance

In fiscal year 2026, Mesoblast's revenue was $120.25 million, an increase of 599.21% compared to the previous year's $17.20 million. Losses were -$57.50 million, -43.71% less than in 2025.

Financial numbers in USD Financial Statements

Analyst Summary

According to 6 analysts, the average rating for MSB stock is "Strong Buy." The 12-month stock price target is $3.91, which is an increase of 63.07% from the latest price.

Price Target

$3.91

(63.07% upside)

Analyst Consensus: Strong Buy

Stock Forecasts

News

Mesoblast price target raised to $39 from $35 at Piper Sandler

Piper Sandler raised the firm’s price target on Mesoblast (MESO) to $39 from $35 and keeps an Overweight rating on the shares. Net Ryoncil revenues were $115M in FY26, and…

9 hours ago - TheFly

Mesoblast Reports Substantial Revenue Growth to US$120M

RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Mesobla...

19 hours ago - GlobeNewsWire

Mesoblast H2 Earnings Call Highlights

Mesoblast NASDAQ: MESO reported $115 million in net revenue for fiscal 2026, its first full year of commercial sales for RYONCIL, the company's FDA-approved allogeneic mesenchymal stromal cell therapy...

19 hours ago - MarketBeat

Mesoblast Earnings Call Transcript: H2 2026

FY 2026 saw $115M net revenue and a 44% reduction in net loss, driven by RYONCIL's successful launch and broad adoption. Major phase III trials in adult GVHD, chronic low back pain, and heart failure are progressing, with double-digit revenue growth expected next year.

21 hours ago - Transcripts

Mesoblast Annual report: H2 2026

Mesoblast has published its H2 2026 annual report on August 26, 2026.

21 hours ago - Filings

Mesoblast Slides: H2 2026

Mesoblast has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 26, 2026.

21 hours ago - Filings

Mesoblast Earnings release: H2 2026

Mesoblast released its H2 2026 earnings on August 26, 2026, summarizing the period's financial results.

21 hours ago - Filings

Mesoblast completes patient treatment in MSB-DR004 in Phase 3 trial

Mesoblast (MESO) announced that it has completed patient treatment in the MSB-DR004 pivotal randomized controlled Phase 3 trial of rexlemestrocel-L for chronic low back pain, CLBP, associated with the...